Anaplastic lymphoma kinase (ALK) is a potent oncogenic driver in lung cancer. ALK tyrosine
kinase inhibitors yield significant benefit in patients with ALK fusion-positive (ALK+) lung …

Protein tyrosine kinases (PTKs) are a class of proteins with tyrosine kinase activity that
phosphorylate tyrosine residues of critical molecules in signaling pathways. Their basal …

Lung cancer accounts for a relatively high proportion of malignant tumors. As the most
prevalent type of lung cancer, non-small cell lung cancer (NSCLC) is characterized by high …

Anaplastic lymphoma kinase (ALK) is a validated molecular target for non-small-cell lung
cancer (NSCLC). The use of tyrosine kinase inhibitors (TKIs) has led to significantly …

Since the discovery of echinoderm microtubule-associated protein-like 4 (EML4) and
anaplastic lymphoma kinase (ALK) gene fusion in non-small cell lung carcinoma (NSCLC) …

Based on superior efficacy and tolerability, targeted therapy is currently preferred over
chemotherapy and/or immunotherapy for actionable gene fusions that occur in late‐stage …

Simple Summary Anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer
(NSCLC) was first reported in 2007. Following the development of crizotinib as a tyrosine …

Lung cancer is the leading cause of malignancy-related death in the United States and the
second most common cancer diagnosis worldwide. In the last two decades, lung cancer …

Introduction Lorlatinib, a third-generation ALK tyrosine kinase inhibitor, improved outcomes
compared with crizotinib in patients with previously untreated ALK-positive advanced …

Background The TP53 tumor suppressor gene plays an important role in preventing and
inhibiting the growth of tumor by regulating cell cycle, apoptosis and DNA repair. Meanwhile …